Scarica l'app Stockscreener
1.69
2.42%
0.04
Pre-mercato:
1.72
0.03
+1.78%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché RNAZ Giù?
Forum
Previsione
Frazionamento azionario
Transcode Therapeutics Inc Borsa (RNAZ) Ultime notizie
TransCode Therapeutics, Inc. (RNAZ) Stock Price, News, Quote & History - Yahoo! Finance Canada
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology - PR Newswire
Transcode Therapeutics (RNAZ) interim CFO becomes reporting insider with no listed stake - Stock Titan
Transcode Therapeutics Inc (NASDAQ: RNAZ) Share Price, RNAZ Stock News, RNAZ Share Price & Updates - kalkine.com.au
Join Today's Live Investor Webinar with TransCode Therapeutics - ACCESS Newswire
Fitzgerald Thomas A Granted 185,000 Derivative Securities in Transcode Therapeutics on September 9, 2026 - Kalkine Media
TransCode Therapeutics Share PriceRNAZ, RNS News, Articles, Quotes, & Charts (NASDAQ:RNAZ) - Proactive financial news
TransCode Therapeutics CFO Resigns, Interim Replacement Named - minichart.com.sg
Form 8K Transcode Therapeutics Inc For: 11 September By Investing.com - Investing.com Nigeria
Transcode Therapeutics announces CFO resignation and interim appointment - Investing.com
TransCode Therapeutics Announces CFO Resignation and Interim Appointment - TipRanks
Transcode Therapeutics (RNAZ) grants CFO 185,000 options with 10-year term - Stock Titan
CFO exit at TransCode Therapeutics (RNAZ) comes with severance tied to future funding - Stock Titan
TransCode Therapeutics Appoints Interim CFO Following Retirement of Tom Fitzgerald - citybuzz -
TransCode Therapeutics Appoints John Tattory As Interim CFO - TradingView
Transcode Therapeutics, Inc. Announces Management Changes, Effective from September 9, 2026 - marketscreener.com
TransCode Therapeutics CFO Tom Fitzgerald retires; John Tattory named interim CFO - Pluang
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer - Yahoo Finance
An RNA-based treatment showed a survival benefit in mice with breast cancer spread to bone - Stock Titan
RNAZ Q4 2024 Earnings: Significant EPS Miss as Clinical-Stage Biotech Reports No Revenue - careplusvn.com
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-than-Expected Loss of $150.64 Per Share Weighs on SharesEarnings Yield Spread - vinanet.vn
TransCode Therapeutics (NASDAQ: RNAZ) logs $24.5M loss and funding strain - Stock Titan
TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TransCode Therapeutics (RNAZ) Holds Above $3.50 as Shares Grind Higher in Quiet SessionExhaustion Gap - vinanet.vn
TransCode Therapeutics (RNAZ) Advances 3.26% to $3.48, Approaching Key Resistance at $3.65Sector Neutral Pair - vinanet.vn
Transcode Therapeutics Inc (RNAZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Transcode Therapeutics Inc (RNAZ) Stock News Today - TradingKey
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - ACCESS Newswire
Why (RNAZ) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Major holder converts preferred shares at Transcode Therapeutics, Inc. (RNAZ) - stocktitan.net
Transcode Therapeutics (RNAZ) major holders disclose convertible preferred stake - Stock Titan
TransCode Therapeutics Updates Preferred Stock Governance Terms - The Globe and Mail
DEFJ lifts TransCode Therapeutics (RNAZ) stake to 83.9% after conversions - Stock Titan
TransCode Therapeutics (RNAZ) Retreats 2.7% to $4.62, Approaching Key Support ZonePre-Earnings Momentum - careplusvn.com
TransCode Therapeutics Q4 2024 Earnings: Wider-than-Expected Loss of -$150.64 Per Share Signals Ongoing Clinical-Stage Cash BurnFinancial Health Score - siam.in
RNAZ|Transcode Therapeutics Inc|Price:5.800|Chg%:-0.130 - TradingKey
Unleash Immuno Oncolytics (RNAZ holder) reports 9.94% TransCode Therapeutics stake - Stock Titan
Transcode Therapeutics Inc (RNAZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TransCode Therapeutics (RNAZ) holder moves toward controlling stake via conversions - Stock Titan
Transcode Therapeutics Inc (RNAZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RNAZ|Transcode Therapeutics Inc|Price:5.930|Chg%:-1.170 - TradingKey
Transcode Therapeutics Inc (RNAZ) Balance Sheet - TradingKey
TransCode Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNAZ - TradingView
RNAZ|Transcode Therapeutics Inc|Price:3.995|Chg%:+0.035 - TradingKey
Transcode Therapeutics Inc (RNAZ) Cash Flow - TradingKey
Transcode Therapeutics Inc (RNAZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Transcode Therapeutics Inc (RNAZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Transcode Therapeutics Inc (RNAZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Transcode Therapeutics Inc (RNAZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Transcode Therapeutics Inc (RNAZ) Institutional Confidence - TradingKey
ON: ON Semiconductor Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
TransCode Therapeutics (NASDAQ: RNAZ) investor conversion leads to 9.9% stake - Stock Titan
TransCode Therapeutics (RNAZ) Proxy Filing Summary - Quartr
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):